

## **Product** Data Sheet

# RTI-13951-33 hydrochloride

Molecular Weight: 532.5

Target: GPR88

Pathway: GPCR/G Protein

Storage: -20°C, sealed storage, away from moisture

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

#### **SOLVENT & SOLUBILITY**

In Vitro

 $\label{eq:DMSO:50 mg/mL (93.90 mM; Need ultrasonic)} $$H_2O:50\ mg/mL\ (93.90\ mM; Need\ ultrasonic)$$ 

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.8779 mL	9.3897 mL	18.7793 mL
	5 mM	0.3756 mL	1.8779 mL	3.7559 mL
	10 mM	0.1878 mL	0.9390 mL	1.8779 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS Solubility: 100 mg/mL (187.79 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.91 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility:  $\geq$  2.08 mg/mL (3.91 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.91 mM); Clear solution

#### **BIOLOGICAL ACTIVITY**

Description	RTI-13951-33 hydrochloride is a potent, selective, and brain-penetrant GPR88 agonist, with an EC <sub>50</sub> of 25 nM in GPR88 cAMP functional assay. RTI-13951-33 hydrochloride reduces alcohol reinforcement and intake behaviors in rats <sup>[1]</sup> .
IC <sub>50</sub> & Target	EC50: 25 nM (GPR88) <sup>[1]</sup>
In Vitro	RTI-13951-33 is a potent, selective, and brain-penetrant GPR88 agonist, with an EC <sub>50</sub> of 25 nM in GPR88 cAMP functional

	assay. RTI-13951-33 elevates [ $^{35}$ S]-GTP $\gamma$ S binding (EC $_{50}$ , 535 nM) in mouse striatal membranes but not in membranes from GPR88 KO mice <sup>[1]</sup> . RTI-13951-33 has weak affinities at kappa opioid receptor (KOR; K $_{i}$ , 2.29 $\mu$ M), vesicular monoamine transporter (VMAT; K $_{i}$ , 4.23 $\mu$ M), and moderate affinity at serotonin transporter (SERT; K $_{i}$ , 0.75 $\mu$ M), however, RTI-13951-33 poorly inhibits SERT (IC $_{50}$ , 25.1±2.7 $\mu$ M) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	RTI-13951-33 (10 and 20 mg/kg, i.p.) dose-dependently decreases alcohol lever responses in a rat model of alcohol self-administration <sup>[1]</sup> . RTI-13951-33 (10 mg/kg, i.p.) has sufficient brain penetration, with $t_{1/2}$ of 48 min and 87 min in rat plasma and brain <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

· bioRxiv. 2020 May.

See more customer validations on www.MedChemExpress.com

#### **REFERENCES**

[1]. Jin C, et al. Discovery of a Potent, Selective, and Brain-Penetrant Small Molecule that Activates the Orphan Receptor GPR88 and Reduces Alcohol Intake. J Med Chem. 2018 Aug 9;61(15):6748-6758.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA